EXPONENT INC·4

Feb 18, 7:43 PM ET

Corrigan Catherine 4

4 · EXPONENT INC · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Exponent (EXPO) CEO Catherine Corrigan Exercises Options, Sells Shares

What Happened

  • Catherine Corrigan, President & CEO and a director of Exponent, exercised stock options on Feb 17, 2026 and immediately sold a portion of the resulting shares. She exercised options to acquire 3,226 shares at $25.41 (cost $81,957) and 2,380 shares at $29.05 (cost $69,139), for a total of 5,606 shares acquired through option exercises. She sold 2,218 shares at $67.16 (proceeds $148,971) and 1,702 shares at $67.14 (proceeds $114,269), totaling 3,920 shares sold for about $263,240.
  • The filing shows corresponding derivative-line entries (marked “disposed” for the options) that reflect conversion of the option instruments into common stock as part of the exercise.

Key Details

  • Transaction date: 2026-02-17; Filing date: 2026-02-18 (timely).
  • Exercise details: 3,226 shares @ $25.41 ($81,957) and 2,380 shares @ $29.05 ($69,139).
  • Sales (open market): 2,218 shares @ $67.16 ($148,971) and 1,702 shares @ $67.14 ($114,269) — total proceeds ≈ $263,240.
  • Shares owned after the transaction: not disclosed in the Form 4.
  • Footnotes: F1 — sales were to cover the option exercise price and taxes; F2 — the stock option vests in four equal annual installments; F3 — not applicable.
  • No 10b5-1 plan or late filing indicated.

Context

  • This pattern (exercise combined with immediate sale of some shares to cover costs and tax withholding) is a common way executives realize shares from options without injecting cash; per the filing, the sales were to cover exercise price and taxes, effectively a cashless transaction for the exercised options.
  • These transactions are routine for option exercises and do not, by themselves, indicate the insider’s view on long-term company prospects.

Insider Transaction Report

Form 4
Period: 2026-02-17
Corrigan Catherine
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-17$25.41/sh+3,226$81,95795,949 total
  • Sale

    Common Stock

    [F1]
    2026-02-17$67.16/sh2,218$148,97193,731 total
  • Exercise/Conversion

    Common Stock

    2026-02-17$29.05/sh+2,380$69,13996,111 total
  • Sale

    Common Stock

    [F1]
    2026-02-17$67.14/sh1,702$114,26994,409 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F3][F2]
    2026-02-173,22612,902 total
    Exercise: $25.41Exp: 2026-07-29Common Stock (3,226 underlying)
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    [F3][F2]
    2026-02-172,38014,278 total
    Exercise: $29.05Exp: 2027-02-16Common Stock (2,380 underlying)
Footnotes (3)
  • [F1]Stock sale was to cover the option exercise price and taxes.
  • [F2]The stock option becomes exercisable in four equal annual installments.
  • [F3]Not applicable.
Signature
By: Wendy Whitehouse For: Catherine Corrigan|2026-02-18

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT